Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03275740




Registration number
NCT03275740
Ethics application status
Date submitted
6/07/2017
Date registered
8/09/2017
Date last updated
31/05/2023

Titles & IDs
Public title
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
Scientific title
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO -CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF 06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING IN HEALTHY ADULT MALE PARTICIPANTS AND OPEN-LABEL AFTER SINGLE SUBCUTANEOUS DOSING IN MALE AND FEMALE PARTICIPANTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA
Secondary ID [1] 0 0
2018-003315-21
Secondary ID [2] 0 0
B7801001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Primary Immune Thrombocytopenia 0 0
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Neurological 0 0 0 0
Neurodegenerative diseases
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PF-06755347 intravenous healthy participant
Treatment: Drugs - Placebo intravenous healthy participant
Treatment: Drugs - PF-06755347 subcutaneous healthy participant
Treatment: Drugs - Placebo subcutaneous healthy participant
Treatment: Drugs - PF-06755347 subcutaneous ITP

Experimental: PF-06755347 intravenous healthy participant - intravenous administration

Placebo Comparator: Placebo intravenous healthy participant - intravenous administration

Experimental: PF-06755347 subcutaneous healthy participant - subcutaneous administration

Placebo Comparator: Placebo subcutaneous healthy participant - subcutaneous administration

Experimental: PF-06755347 subcutaneous ITP - subcutaneous


Treatment: Drugs: PF-06755347 intravenous healthy participant
Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.

Treatment: Drugs: Placebo intravenous healthy participant
Placebo comparator

Treatment: Drugs: PF-06755347 subcutaneous healthy participant
single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.

Treatment: Drugs: Placebo subcutaneous healthy participant
placebo comparator

Treatment: Drugs: PF-06755347 subcutaneous ITP
single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Timepoint [1] 0 0
Baseline (study day -2) through study completion (study day 36 for intravenous dose cohorts 1 - 6, and study day 71 for subcutaneous dose cohorts.
Primary outcome [2] 0 0
Number of Participants With Clinical Laboratory Abnormalities
Timepoint [2] 0 0
Baseline, study days 1, 2, 4, 6, 8, 11, 15, 22, 29 and 36 for i.v. dose cohorts 1 - 6, and Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 50 and day 71 for subcutaneous dose cohorts.
Primary outcome [3] 0 0
Number of Participants With Categorical Vital Signs Data
Timepoint [3] 0 0
Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, 29, and day 36 for i.v. dose cohorts 1 - 6 and Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 50 and day 71 for subcutaneous dose cohorts.
Primary outcome [4] 0 0
Number of Participants With Abnormal Electrocardiogram (ECG)
Timepoint [4] 0 0
Baseline (study day 1, pre-dose), study days 1 (post dose), 2, 4, 6, 8, 11, 22, 36 (end of study visit for intravenous dose cohorts 1 - 6, and end of study visit day 71) for subcutaneous dose cohorts.
Secondary outcome [1] 0 0
Maximum Observed Plasma Concentration (Cmax)
Timepoint [1] 0 0
Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary outcome [2] 0 0
Dose Normalized Maximum Observed Plasma Concentration Cmax
Timepoint [2] 0 0
Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary outcome [3] 0 0
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Timepoint [3] 0 0
Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary outcome [4] 0 0
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Timepoint [4] 0 0
Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary outcome [5] 0 0
Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Timepoint [5] 0 0
Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary outcome [6] 0 0
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
Timepoint [6] 0 0
Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary outcome [7] 0 0
Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
Timepoint [7] 0 0
Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary outcome [8] 0 0
Plasma Decay Half-Life (t1/2)
Timepoint [8] 0 0
Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary outcome [9] 0 0
Apparent Clearance (CL)
Timepoint [9] 0 0
Hours 0, 12, 24, 48, 72, 120, 168 for all cohorts. Hours 1, 3, 5, & 8 for all i.v. cohorts. Hour 36 for i.v. cohorts 1-2. Days 15, 22, 29, and 36 for subcutaneous and i.v. cohorts 5 exp & 6. Days 5, 11, 50 & 71 for subcutaneous cohorts
Secondary outcome [10] 0 0
Incidence of Anti-Drug Antibody (ADA)
Timepoint [10] 0 0
Baseline, study days 8, 15, and 36 for all dose cohorts plus day 71 for subcu cohorts
Secondary outcome [11] 0 0
Characterization of biomarker changes
Timepoint [11] 0 0
Day -1, hours 0, 5, 12, 24, 48, 72 for all cohorts. Hours 1 (or end of infusion, 8, 120 and days 11 & 29 for i.v. cohorts Days 5, 8, 15, 36 & 71 for subcutaneous cohorts.

Eligibility
Key inclusion criteria
Inclusion Criteria Healthy male participants:

- at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy
is defined as no clinically relevant abnormalities identified by a detailed medical
history, full physical examination, including oral temperature, blood pressure (BP)
and pulse rate measurement, pulse oximetry, 12 lead ECG or clinical laboratory tests.

- Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study.

- Chest X ray with no evidence of current, active tuberculosis (TB) or previous inactive
TB, general infections, heart failure, malignancy, or other clinically significant
abnormalities taken at Screening or within 3 months prior to Screening and read by a
qualified radiologist.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion Criteria for Healthy male participants:

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at the time of dosing).

- Participants with a history of autoimmune disorders and other conditions that
compromise or impair the immune system (including but not limited to: Crohns Disease,
rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Graves disease, and
asthma) or have a current positive result for the following; rheumatoid factor,
anti-nuclear antibody, or abnormal free triiodothyronine (T3), free thyroxine (T4),
thyroid stimulating hormone (TSH), or thyroid stimulating antibody (TSAb) suggestive
of thyroid disease.

- Subjects with a history of allergic or anaphylactic reaction to any drug including
immunoglobulin.

- History of active infections within 28 days prior to the screening visit.

- Subjects with a history of or current positive results for any of the following
serological tests: Hepatitis B surface antigen (HepBsAg), Hepatitis B core antibody
(HepBcAb), Hepatitis C antibody (HCVAb) or human immunodeficiency virus (HIV).

- Subjects with a history of thromboembolic events.

- History of TB or active, latent or inadequately treated TB infection. All positive TB
test result(s) are exclusionary

- Male subjects with partners currently pregnant; male subjects able to father children
who are unwilling or unable to use a highly effective method of contraception as
outlined in this protocol for the duration of the study.

- Inclusion Criteria for ITP participants:

Female participants may be of childbearing potential or non-childbearing potential.

-Diagnosis of Primary ITP. ITP must be diagnosed in accordance with established guidelines.
ITP duration-Persistent (>3 months and =12 months) OR Chronic (>12 months).

AND

- Platelet count 30-75 x 10E9/L (inclusive) with criteria achieved on 2 qualifying
counts at least 5 days apart and within approx. 10 days of dosing

- Participants must have received and responded to IVIg or corticosteroids as treatment
for ITP (response is defined as achievement of platelet count >50 x 109/L and doubling
of platelet count from baseline).

--Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study.

- BMI of 17.5 to 30.5 kg/m2 and a total body weight >40 kg (88 lbs).

Exclusion Criteria for ITP participants

- History of clinically significant hematological (other than ITP), renal, endocrine,
metabolic, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
neurologic, or allergic disease (but excluding untreated, asymptomatic, seasonal
allergies at the time of dosing).

- Chest X-ray with evidence of current, active TB, previous inactive TB, general
infections, heart failure, malignancy, or other clinically significant abnormalities.

Chest x-ray must be taken at Screening or within 3 months prior to Screening and read by a
qualified radiologist.

- Any bleeding event requiring medical evaluation or treatment in the 4 weeks prior to
screening or current bleeding event that requires treatment.

- Scheduled or anticipated invasive procedures (eg, surgery, dental procedures) within
28 days following PF-06755347 dosing.

- Splenectomy within =180 days prior to PF-06755347 dosing or splenectomy planned during
the period of the study.

- History of any active autoimmune disorder (other than ITP) or other conditions that
may compromise or impair the immune system (including but not limited to: Crohn's
Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Graves'
disease, and asthma).

- History of allergic or anaphylactic reaction to any drug including immunoglobulin.

- History of active infections within 28 days prior to the screening visit.

- History of Hepatitis B, Hepatitis C or HIV or current positive results for any of the
following serological tests - HBsAg, HBcAb, HCVAb or HIV.

- History of thromboembolic events

- Hemoglobin <9 g/dL.

- Positive Direct Coombs test

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/07/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
6/01/2023
Sample size
Target
Accrual to date
Final
58
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Connecticut
Country [2] 0 0
Belgium
State/province [2] 0 0
Brussels
Country [3] 0 0
New Zealand
State/province [3] 0 0
Christchurch
Country [4] 0 0
Spain
State/province [4] 0 0
Madrid
Country [5] 0 0
Spain
State/province [5] 0 0
Sevilla
Country [6] 0 0
United Kingdom
State/province [6] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This phase 1 single ascending dose study will provide a first in human assessment of safety
and tolerability of PF-06755347 in healthy adult males as well as adult males and females
with Immune Thrombocytopenia (ITP). Pharmacokinetics and pharmacodynamics will also be
evaluated.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03275740
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03275740